Resverlogix Corp.

Resverlogix Corp.

November 14, 2006 09:31 ET

Expert Panel Reviews Resverlogix Corp. ApoA-I Enhancing Technologies

CHICAGO, ILLINOIS--(CCNMatthews - Nov. 14, 2006) - Resverlogix Corp. ("Resverlogix") (TSX:RVX), is pleased to announce that the Company has conducted its first Clinical Advisory meeting in Chicago, prior to the American Heart Association's Scientific meetings. Resverlogix's lead candidate RVX208 has repeatedly shown the pronounced potency to increase plasma ApoA-I levels in animal models. ApoA-I is a validated key target for cardiovascular disease (CVD) protection. After a thorough review of Resverlogix science the expert panel has recommended that Resverlogix constitute a clinical advisory board for its ApoA-I enhancing lead program NexVas™ PR.

Attending the meeting was Dr. Bo Angelin, Professor of Clinical Metabolism at Karolinska Institute, Sweden, who stated, "ApoA-I is a key validated target for the treatment and prevention of cardiovascular risk. The progress Resverlogix has made in their lead technology program NexVas PR represents an important new approach to reducing the burden of CVD. I look forward to following the development of this interesting project."

"It is fascinating to launch RVX208, a novel molecule increasing ApoA-I, to clinical studies," said Dr. Jan Johansson, SVP Clinical Affairs, Resverlogix. "The acceleration of our clinical program through the support of these outstanding experts in the field will greatly enhance the NexVas PR program. The enhancement of ApoA-I by NexVas PR has the potential to become a first in class therapeutic for the treatment of atherosclerosis and cardiovascular disease."

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company in the development of novel therapies for important global medical markets with significant unmet medical needs. The Company's primary focus is to conduct leading research, development and commercialization of novel therapeutics that address the risk of Cardiovascular Disease (CVD). Through successful research efforts, the Company has expanded its CVD platform to three programs, each addressing different targets for specific commercial markets. NexVas™ Plaque Reduction (NexVas PR), is the Company's primary program that targets ApoA-I enhancement via novel small molecules for plaque stabilization and regression. NexVas™ Vascular Inflammation (NexVas VI) is the Company's second CVD program, a discovery stage technology focused on molecular targets of vascular inflammation. ReVas™ the Company's third CVD program is dedicated to the research and development of therapeutic compounds to be used with medical devices and biomaterials for the local non-systemic treatment of CVD, in particular restenosis. The Company has partnered ReVas™ with Medtronic Inc., a world leading medical technology company. The Company's secondary focus is TGF-Beta Shield™, a program that aims to address the unmet medical needs of burgeoning grievous diseases, such as cancer and fibrosis, with a TGF- Beta inhibitor. Resverlogix is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for the treatment of unmet human diseases. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information, please visit our web site at

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

Contact Information

  • Resverlogix Corp.
    Kenneth Lebioda
    Senior Vice President, Business & Market Development
    (403) 254-9252 ext. 227
    (403) 256-8495 (FAX)
    Resverlogix Corp.
    Theresa Kennedy
    Vice President, Corporate Communications
    (604) 538-7072
    (403) 256-8495 (FAX)